ClinicalTrials.gg
CompletedNCT02776735SKYPPUpdated Oct 15, 2024Results posted

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

A Phase 2 interventional study of Sarilumab in Juvenile Idiopathic Arthritis, sponsored by Sanofi. Completed at 30 sites in 15 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Arthritis, Juvenile with a site in Poland — 7 open to participants now, 8 under way, 7 of them phase 3. Arthritis, Juvenile · Poland.

Enrollment
13th of 28
102 · median 93
Started
2016
with 1 other
Phase 2
Only one
of the 29
Registered
14th of 29
by date
Lead sponsor
1 of 29
Sanofi

Among the 29 studies in Arthritis, Juvenile with a site in Poland, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2016, is the only one in phase 2, and was the 14th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

7 of the 29 studies in Arthritis, Juvenile with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Arthritis, Juvenile with a site in Poland, or all of them as a file.
02

Study summary

Primary Objective:

To describe the pharmacokinetic (PK) profile of sarilumab in participants aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate treatment of this population

Secondary Objective:

To describe the pharmacodynamic (PD) profile, the efficacy and the long-term safety of sarilumab in participants with pcJIA.

Read the detailed description

For 73 participants enrolled in the dose-finding and second portions, the total study duration per participant was up to 166 weeks that consists of a 4- week screening, a 12-week core treatment phase, a 144-week extension phase, and a 6-week post-treatment follow-up. For 29 participants enrolled in the third portion, the total study duration per participant was up to 106 weeks that consists of a 4- week screening, a 12-week core treatment phase, a 84-week extension phase, and a 6-week post-treatment follow-up.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria :

  • Male and female participants aged ≥2 and ≤17 years (or country specified age requirement) at the time of the screening visit.
  • Diagnosis of rheumatoid factor-negative or rheumatoid factor positive polyarticular Juvenile Idiopathic Arthritis (JIA) subtype or oligoarticular extended JIA subtype according to the International League of Associations for Rheumatology (ILAR) 2001 Juvenile Idiopathic Arthritis Classification Criteria with at least 5 active joints as per American College of Rheumatology (ACR) definition for "active arthritis" at Screening
  • Participant with an inadequate response to current treatment and considered as a candidate for a biologic disease modifying antirheumatic drug (DMARD) as per investigator's judgment

Exclusion criteria:

  • Body weight \<10 kg or >60 kg for participants enrolled in the 3 ascending dose cohorts, then body weight \<10 kg for participants subsequently enrolled at the selected dose-regimen.
  • If nonsteroidal anti-inflammatory drugs (NSAIDs) [including cyclo oxygenase-2 inhibitors (COX-2)] taken, dose stable for \<2 weeks prior to the baseline visit and/or dosing prescribed outside of approved label.
  • If non-biologic DMARD taken, dose stable for \<6 weeks prior to the baseline visit or at a dose exceeding the recommended dose as per local labeling.
  • If oral taken, dose exceeding equivalent prednisone dose 0.5 mg/kg/day (or 30 mg/day) within 2 weeks prior to baseline.
  • Use of parenteral or intra-articular glucocorticoid injection within 4 weeks prior to baseline.
  • Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.
  • Treatment with any biologic treatment for pcJIA within 5 half-lives prior to the first dose of sarilumab.
  • Treatment with a Janus kinase inhibitor within 4 weeks prior to the first dose of sarilumab; and treatment with growth hormone within 4 weeks prior to the first dose of sarilumab (the required off treatment periods and procedures may vary according to local requirements).
  • Treatment with any biologic or non-biologic product within 8 weeks or 5 half-lives prior to baseline, whichever is longer.
  • Lipid lowering drug stable for less than 6 weeks prior to screening.
  • Exclusion related to tuberculosis (TB).
  • Exclusion criteria related to past or current infection other than tuberculosis.
  • Any live, attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, rubella vaccines. Killed or inactive vaccine may be permitted based on the Investigator's judgment.
  • Exclusion related to history of a systemic reaction to any biologic drug and known hypersensitivity to any constituent of the product.
  • Laboratory abnormalities at the screening visit (identified by the central laboratory).
  • Pregnant or breast-feeding female adolescent participants.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Sarilumab

    Participants received one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants received the selected dose regimen once this was identified. Sarilumab was given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for 73 participants enrolled in dose-finding and second portions and 84 weeks for approximately 29 participants enrolled in third portion)

    Drug: Sarilumab

Interventions

  • Pharmaceutical form:Solution Route of administration: Subcutaneous

    Also known as: SAR153191 (REGN88)

06

What researchers measure

Primary outcomes

  1. Maximum Serum Concentration (Cmax) of Sarilumab at Week 12

    The Cmax was defined as maximum serum concentration. The values reported are mean and standard deviation.

    Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12

  2. Area Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 12

    The AUC0-t was defined as area under the concentration in serum versus time curve calculated using the trapezoidal method during a dose interval (tau). The values reported are mean and standard deviation.

    Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12

  3. Concentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 12

    The Ctrough was defined as concentration observed before treatment administration during repeated dosing from baseline to Week 12. The values reported are mean and standard deviation.

    Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12

Secondary outcomes

  1. Cohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12

    Serum concentrations of hs-CRP was determined to assess the Pharmacodynamic (PD) effects of sarilumab. The values reported are mean and standard deviation.

    Time frame: Baseline (Day 1) and Week 12

  2. Cohort 2: Change From Baseline in High-Sensitivity C-reactive Protein at Weeks 12, 24, 48, 96, and 156

    Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  3. Change From Baseline in Interleukin-6 (IL-6) at Week 12

    Serum concentrations of IL-6 was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

    Time frame: Baseline (Day 1) and Week 12

  4. Change From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 12

    Serum concentrations of sIL-6R was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

    Time frame: Baseline (Day 1) and Week 12

  5. Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12

    JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Week 12

  6. Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 30 Response at Weeks 12, 24, 48, 96, and 156

    JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Weeks 12, 24, 48, 96, and 156

  7. Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 12

    JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Week 12

  8. Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Weeks 12, 24, 48, 96, and 156

    JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Weeks 12, 24, 48, 96, and 156

  9. Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 12

    JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Week 12

  10. Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Weeks 12, 24, 48, 96, and 156

    JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Weeks 12, 24, 48, 96, and 156

  11. Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 12

    JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Week 12

  12. Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Weeks 12, 24, 48, 96, and 156

    JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Weeks 12, 24, 48, 96, and 156

  13. Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 12

    JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Week 12

  14. Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Weeks 12, 24, 48, 96, and 156

    JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

    Time frame: Weeks 12, 24, 48, 96, and 156

  15. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using visual analog scale (VAS), Childhood Health Questionnaire Disability Index (CHAQ-DI) and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).

    Time frame: Baseline (Day 1) and Week 12

  16. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  17. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).

    Time frame: Baseline (Day 1) and Week 12

  18. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  19. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Week 12

  20. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  21. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.

    Time frame: Baseline (Day 1) and Week 12

  22. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  23. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Week 12

  24. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  25. Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Week 12

  26. Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Weeks 12, 24, 48, 96, and 156

    The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  27. Cohorts 1 and 3: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) at Week 12

    The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.

    Time frame: Baseline (Day 1) and Week 12

  28. Cohort 2: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score at Weeks 12, 24, 48, 96, and 156

    The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.

    Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156

  29. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

    An adverse events (AEs) is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event. TEAEs are defined as AEs that develop or worsen during the on-treatment period \[that is, from the time of first dose of study treatment up to 6 weeks after the last administration of the study treatment\].

    Time frame: From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3

  30. Number of Participants With Local Site Reactions

    Participants were observed for at least 30 minutes after each study treatment administration either on site or at home and any local reactions were noted in the diary regardless of being clinically significant.

    Time frame: From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3

07

Results

Posted Oct 15, 2024

Participant flow

Group A: \>=30kg and \<=60kg and Group B: \<30kg and \>=10kg. Portion 1 of study enrolled participants into 3 dosing regimens (Cohort 1, 2 and 3). Cohort 1: dose capped at 150mg q2w (Group A:2mg/kg q2w; Group B:2.5mg/kg q2w). Cohort 2: dose capped at 200mg q2w (Group A:3mg/kg q2w; Group B:4mg/kg q2w). Cohort 3: dose capped at 150mg qw (Group A:2mg/kg qw; Group B:2.5mg/kg qw). All 3 cohorts in Portion 1 received 12-week core treatment phase and eligible participants entered 144-week extension phase.

Participant flow — Overall Study
MilestoneCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Started76433169
Treated76423169
Completed66382767
Not completed105402
Withdrew: Adverse event000101
Withdrew: Lost to follow-up000100
Withdrew: Withdrawal by parent/guardian002200
Withdrew: Withdrawal by subject100001
Withdrew: Other003000

Outcome measures

PrimaryMaximum Serum Concentration (Cmax) of Sarilumab at Week 12

The Cmax was defined as maximum serum concentration. The values reported are mean and standard deviation.

Time frame:
Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Reported as:
Mean · milligram per liter (mg/L)
Maximum Serum Concentration (Cmax) of Sarilumab at Week 12
milligram per liter (mg/L)Cohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Maximum Serum Concentration (Cmax) of Sarilumab at Week 127.57 ± 4.1413.7 ± 2.5222.0 ± 8.0733.6 ± 7.1632.0 ± 7.2731.0 ± 7.98
PrimaryArea Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 12

The AUC0-t was defined as area under the concentration in serum versus time curve calculated using the trapezoidal method during a dose interval (tau). The values reported are mean and standard deviation.

Time frame:
Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Reported as:
Mean · day*mg/L
Area Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 12
day*mg/LCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Area Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 1261.4 ± 25.2106 ± 36.8212 ± 77.2318 ± 90.0202 ± 55.0192 ± 60.7
PrimaryConcentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 12

The Ctrough was defined as concentration observed before treatment administration during repeated dosing from baseline to Week 12. The values reported are mean and standard deviation.

Time frame:
Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Reported as:
Mean · mg/L
Concentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 12
mg/LCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Concentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 121.30 ± 0.9521.32 ± 1.275.76 ± 3.579.88 ± 5.4222.2 ± 7.1223.2 ± 8.28
SecondaryCohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12

Serum concentrations of hs-CRP was determined to assess the Pharmacodynamic (PD) effects of sarilumab. The values reported are mean and standard deviation.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · mg/L
Cohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12
mg/LCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12-1.00 ± 2.53-0.52 ± 3.64-5.71 ± 8.90-6.83 ± 11.74
SecondaryCohort 2: Change From Baseline in High-Sensitivity C-reactive Protein at Weeks 12, 24, 48, 96, and 156

Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · mg/L
Cohort 2: Change From Baseline in High-Sensitivity C-reactive Protein at Weeks 12, 24, 48, 96, and 156
mg/LCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-3.54 ± 33.57-20.66 ± 48.35
Week 24-8.54 ± 19.17-11.72 ± 23.54
Week 48-9.93 ± 21.60-12.57 ± 24.23
Week 96-9.39 ± 21.65-13.88 ± 25.96
Week 156-5.10 ± 14.68-12.30 ± 26.69
SecondaryChange From Baseline in Interleukin-6 (IL-6) at Week 12

Serum concentrations of IL-6 was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · nanogram (ng)/L
Change From Baseline in Interleukin-6 (IL-6) at Week 12
nanogram (ng)/LCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Change From Baseline in Interleukin-6 (IL-6) at Week 121.27 ± 9.7913.65 ± 18.2043.71 ± 113.4211.36 ± 35.8166.21 ± 86.219.20 ± 26.50
SecondaryChange From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 12

Serum concentrations of sIL-6R was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · ng/mL
Change From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 12
ng/mLCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Change From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 1240.09 ± 49.75101.50 ± 129.59316.77 ± 129.29388.33 ± 185.82535.76 ± 98.12582.95 ± 149.52
SecondaryCohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12

JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Week 12
Reported as:
Number · percentage of participants with response
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12
percentage of participants with responseCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12100100100100
SecondaryCohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 30 Response at Weeks 12, 24, 48, 96, and 156

JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Weeks 12, 24, 48, 96, and 156
Reported as:
Number · percentage of participants with response
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 30 Response at Weeks 12, 24, 48, 96, and 156
percentage of participants with responseCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12100100
Week 24100100
Week 48100100
Week 9697.2100
Week 15694.1100
SecondaryCohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 12

JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Week 12
Reported as:
Number · percentage of participants with response
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 12
percentage of participants with responseCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 1280.0100100100
SecondaryCohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Weeks 12, 24, 48, 96, and 156

JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Weeks 12, 24, 48, 96, and 156
Reported as:
Number · percentage of participants with response
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Weeks 12, 24, 48, 96, and 156
percentage of participants with responseCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 1294.996.6
Week 24100100
Week 48100100
Week 9697.2100
Week 15694.1100
SecondaryCohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 12

JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Week 12
Reported as:
Number · percentage of participants with response
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 12
percentage of participants with responseCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 1260.040.0100100
SecondaryCohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Weeks 12, 24, 48, 96, and 156

JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Weeks 12, 24, 48, 96, and 156
Reported as:
Number · percentage of participants with response
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Weeks 12, 24, 48, 96, and 156
percentage of participants with responseCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 1274.489.7
Week 2487.296.3
Week 4889.5100
Week 9697.2100
Week 15694.1100
SecondaryCohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 12

JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Week 12
Reported as:
Number · percentage of participants with response
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 12
percentage of participants with responseCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 1260.020.066.760.0
SecondaryCohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Weeks 12, 24, 48, 96, and 156

JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Weeks 12, 24, 48, 96, and 156
Reported as:
Number · percentage of participants with response
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Weeks 12, 24, 48, 96, and 156
percentage of participants with responseCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 1243.648.3
Week 2464.174.1
Week 4868.488.5
Week 9680.695.8
Week 15676.5100
SecondaryCohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 12

JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Week 12
Reported as:
Number · percentage of participants with response
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 12
percentage of participants with responseCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 120033.340.0
SecondaryCohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Weeks 12, 24, 48, 96, and 156

JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.

Time frame:
Weeks 12, 24, 48, 96, and 156
Reported as:
Number · percentage of participants with response
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Weeks 12, 24, 48, 96, and 156
percentage of participants with responseCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 1212.824.1
Week 2423.148.1
Week 4842.153.8
Week 9647.270.8
Week 15652.987.5
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using visual analog scale (VAS), Childhood Health Questionnaire Disability Index (CHAQ-DI) and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · joint
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12
jointCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12-14.40 ± 2.159-11.20 ± 2.871-16.50 ± 4.137-14.40 ± 5.573
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · joint
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Weeks 12, 24, 48, 96, and 156
jointCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-15.15 ± 1.511-12.38 ± 1.519
Week 24-16.66 ± 1.497-13.26 ± 1.575
Week 48-17.24 ± 1.547-13.73 ± 1.618
Week 96-16.47 ± 1.682-13.79 ± 1.751
Week 156-18.65 ± 2.334-13.88 ± 2.495
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · joint
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12
jointCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12-7.80 ± 2.083-5.80 ± 2.267-7.83 ± 2.600-13.00 ± 4.219
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · joint
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Weeks 12, 24, 48, 96, and 156
jointCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-9.71 ± 1.249-9.21 ± 1.540
Week 24-10.40 ± 1.330-10.63 ± 1.559
Week 48-10.99 ± 1.498-10.73 ± 1.525
Week 96-11.14 ± 1.661-10.42 ± 1.493
Week 156-11.29 ± 2.203-11.81 ± 2.550
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12
units on a scaleCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12-0.80 ± 0.242-1.08 ± 0.239-0.42 ± 0.173-0.75 ± 0.213
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · units on a scale
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Weeks 12, 24, 48, 96, and 156
units on a scaleCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-0.77 ± 0.092-0.74 ± 0.113
Week 24-0.90 ± 0.096-0.95 ± 0.132
Week 48-0.88 ± 0.084-1.08 ± 0.119
Week 96-0.92 ± 0.109-1.13 ± 0.136
Week 156-1.07 ± 0.163-1.20 ± 0.169
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · mg/L
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12
mg/LCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12-1.00 ± 1.130-1.67 ± 1.139-5.71 ± 3.633-2.54 ± 1.845
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · mg/L
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Weeks 12, 24, 48, 96, and 156
mg/LCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-3.84 ± 5.437-20.66 ± 9.304
Week 24-8.54 ± 3.151-11.72 ± 4.371
Week 48-9.93 ± 3.505-12.57 ± 4.664
Week 96-9.39 ± 3.608-13.88 ± 5.414
Week 156-5.10 ± 3.671-12.30 ± 6.672
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12
units on a scaleCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12-3.56 ± 0.969-6.30 ± 0.397-4.55 ± 0.509-5.68 ± 1.163
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · units on a scale
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Weeks 12, 24, 48, 96, and 156
units on a scaleCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-4.50 ± 0.248-4.09 ± 0.367
Week 24-4.99 ± 0.237-5.01 ± 0.341
Week 48-5.27 ± 0.263-5.25 ± 0.321
Week 96-5.30 ± 0.306-5.35 ± 0.347
Week 156-5.66 ± 0.396-5.73 ± 0.437
SecondaryCohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12
units on a scaleCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12-3.30 ± 1.014-3.16 ± 1.364-3.05 ± 0.992-5.00 ± 0.969
SecondaryCohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Weeks 12, 24, 48, 96, and 156

The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · units on a scale
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Weeks 12, 24, 48, 96, and 156
units on a scaleCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
Week 12-3.73 ± 0.335-4.01 ± 0.435
Week 24-4.38 ± 0.313-4.39 ± 0.475
Week 48-4.21 ± 0.356-4.64 ± 0.510
Week 96-4.36 ± 0.387-5.09 ± 0.521
Week 156-4.19 ± 0.738-5.01 ± 0.636
SecondaryCohorts 1 and 3: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) at Week 12

The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Cohorts 1 and 3: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) at Week 12
units on a scaleCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
JADAS-27-ESR: Week 12-15.4 ± 2.98-19.1 ± 3.05-20.0 ± 3.82-19.4 ± 6.01
JADAS-27-CRP: Week 12-16.0 ± 2.78-18.1 ± 2.62-18.5 ± 3.42-21.1 ± 4.96
Clinical JADAS-27: Week 12-16.1 ± 2.77-18.1 ± 2.62-18.3 ± 3.28-21.1 ± 4.96
SecondaryCohort 2: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score at Weeks 12, 24, 48, 96, and 156

The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.

Time frame:
Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Reported as:
Mean · units on a scale
Cohort 2: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score at Weeks 12, 24, 48, 96, and 156
units on a scaleCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kg
JADAS-27-ESR: Week 12-18.9 ± 1.46-16.9 ± 1.51
JADAS-27-ESR: Week 24-21.9 ± 1.32-18.3 ± 1.72
JADAS-27-ESR: Week 48-22.3 ± 1.45-19.4 ± 1.61
JADAS-27-ESR: Week 96-22.4 ± 1.69-20.4 ± 1.84
JADAS-27-ESR: Week 156-23.2 ± 2.06-20.6 ± 2.57
JADAS-27-CRP: Week 12-18.2 ± 1.26-16.3 ± 1.42
JADAS-27-CRP: Week 24-20.9 ± 1.20-18.8 ± 1.53
JADAS-27-CRP: Week 48-21.6 ± 1.23-19.4 ± 1.58
JADAS-27-CRP: Week 96-21.9 ± 1.58-20.1 ± 1.50
JADAS-27-CRP: Week 156-21.8 ± 2.01-20.2 ± 2.24
Clinical JADAS-27: Week 12-17.9 ± 1.19-16.0 ± 1.32
Clinical JADAS-27: Week 24-20.5 ± 1.14-18.0 ± 1.46
Clinical JADAS-27: Week 48-21.0 ± 1.22-18.8 ± 1.49
Clinical JADAS-27: Week 96-21.2 ± 1.52-19.5 ± 1.60
Clinical JADAS-27: Week 156-21.2 ± 1.85-19.3 ± 2.14
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

An adverse events (AEs) is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event. TEAEs are defined as AEs that develop or worsen during the on-treatment period \[that is, from the time of first dose of study treatment up to 6 weeks after the last administration of the study treatment\].

Time frame:
From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
ParticipantsCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Any TEAE76403059
Any treatment emergent SAE203300
SecondaryNumber of Participants With Local Site Reactions

Participants were observed for at least 30 minutes after each study treatment administration either on site or at home and any local reactions were noted in the diary regardless of being clinically significant.

Time frame:
From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3
Reported as:
Count of participants · Participants
Number of Participants With Local Site Reactions
ParticipantsCohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kg
Number of Participants With Local Site Reactions10211931

Adverse events

Collected over From the first administration of study treatment (Day 1) up to end of study, maximum of 162 weeks for portions 1 and 2 and 102 weeks for portion 3.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: >= 30 kg and <= 60 kg0/7 (0%)2/7 (28.6%)7/7 (100%)
Cohort 2 (From Baseline): >= 30 kg and <= 60 kg0/42 (0%)3/42 (7.1%)39/42 (92.9%)
Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kg0/4 (0%)0/4 (0%)4/4 (100%)
Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 3: >= 30 kg and <= 60 kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 1: < 30 kg and >= 10 kg0/6 (0%)0/6 (0%)6/6 (100%)
Cohort 2 (From Baseline): < 30 kg and >= 10 kg0/31 (0%)3/31 (9.7%)29/31 (93.5%)
Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kg0/5 (0%)0/5 (0%)5/5 (100%)
Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kg0/5 (0%)0/5 (0%)5/5 (100%)
Cohort 3: < 30 kg and >= 10 kg0/9 (0%)0/9 (0%)9/9 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort 1: >= 30 kg and <= 60 kgCohort 2 (From Baseline): >= 30 kg and <= 60 kgCohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kgCohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kgCohort 3: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2 (From Baseline): < 30 kg and >= 10 kgCohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kgCohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kgCohort 3: < 30 kg and >= 10 kg
Infectious MononucleosisInfections and infestations1/70/420/40/60/60/60/310/50/50/9
SyncopeNervous system disorders1/70/420/40/60/60/60/310/50/50/9
Inguinal HerniaGastrointestinal disorders0/70/420/40/60/60/61/310/50/50/9
Pancreatic PseudocystGastrointestinal disorders0/70/420/40/60/60/61/310/50/50/9
Pancreatitis AcuteGastrointestinal disorders0/70/420/40/60/60/61/310/50/50/9
Bone TuberculosisInfections and infestations0/70/420/40/60/60/61/310/50/50/9
Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders0/70/420/40/60/60/61/310/50/50/9
Acute SinusitisInfections and infestations0/71/420/40/60/60/60/310/50/50/9
Ligament RuptureInjury, poisoning and procedural complications0/71/420/40/60/60/60/310/50/50/9
Meniscus InjuryInjury, poisoning and procedural complications0/71/420/40/60/60/60/310/50/50/9
Most frequent other events
Showing 10 of 124
Most frequent other events
EventCohort 1: >= 30 kg and <= 60 kgCohort 2 (From Baseline): >= 30 kg and <= 60 kgCohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kgCohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kgCohort 3: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2 (From Baseline): < 30 kg and >= 10 kgCohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kgCohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kgCohort 3: < 30 kg and >= 10 kg
Upper Respiratory Tract InfectionInfections and infestations4/76/423/41/62/62/63/310/51/52/9
NeutropeniaBlood and lymphatic system disorders3/710/421/40/61/61/615/312/50/56/9
NasopharyngitisInfections and infestations0/711/420/44/63/61/617/310/53/53/9
Ligament SprainInjury, poisoning and procedural complications1/72/422/40/60/60/60/310/50/50/9
VomitingGastrointestinal disorders0/72/420/40/61/60/63/312/52/51/9
PharyngitisInfections and infestations1/76/420/40/60/62/61/312/50/50/9
RhinitisInfections and infestations2/74/420/40/60/61/63/311/52/53/9
Dermatitis AllergicSkin and subcutaneous tissue disorders0/70/420/40/60/60/61/312/50/50/9
PneumoniaInfections and infestations0/70/420/40/62/60/62/310/50/50/9
ArthralgiaMusculoskeletal and connective tissue disorders0/72/420/40/60/62/63/310/50/50/9

Baseline characteristics

All treated population included participants who signed informed consent and received at least 1 dose of the study treatment.

Age, Continuous
Age, Continuous(years)Cohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kgTotal
Mean12.3 ± 3.36.5 ± 3.212.6 ± 3.05.4 ± 3.113.7 ± 3.04.8 ± 2.49.4 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kgTotal
Female5535233677
Male21783324
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: >= 30 kg and <= 60 kgCohort 1: < 30 kg and >= 10 kgCohort 2: >= 30 kg and <= 60 kgCohort 2: < 30 kg and >= 10 kgCohort 3: >= 30 kg and <= 60 kgCohort 3: < 30 kg and >= 10 kgTotal
American Indian or Alaska Native0000000
Asian0010001
Black or African American0000000
Native Hawaiian or Other Pacific Islander0000000
White6339284888
Not Reported0123017
Unknown1200205
08

Study locations

30 sites
  • Children's Hospital Los Angeles Site Number : 8400416
    Los Angeles, California 90027, United States
  • Investigational Site Number : 0320060
    Caba, Buenos Aires C1270AAN, Argentina
  • Investigational Site Number : 0320004
    Tucumán, T4000AXL, Argentina
  • Investigational Site Number : 1240112
    Montréal, Quebec H3T1C5, Canada
  • Investigational Site Number : 1520016
    Concepcion, Biobío, Chile
  • Investigational Site Number : 2030041
    Brno, 62500, Czechia
  • Investigational Site Number : 2460040
    Helsinki, 00029 HUS, Finland
  • Investigational Site Number : 2500040
    Paris, 75015, France
  • Investigational Site Number : 2760064
    Berlin, 13125, Germany
  • Investigational Site Number : 2760061
    Bremen, 28205, Germany
  • Investigational Site Number : 2760062
    Hamburg, 22081, Germany
  • Investigational Site Number : 2760060
    Sankt Augustin, 53757, Germany
  • Investigational Site Number : 3800052
    Roma, Italy
  • Investigational Site Number : 4840061
    Guadalajara, Jalisco 44620, Mexico
  • Investigational Site Number : 4840060
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 5280020
    Utrecht, 3584 EA, Netherlands
  • Investigational Site Number : 6160074
    Bydgoszcz, Kujawsko-pomorskie 85-667, Poland
  • Investigational Site Number : 6160070
    Lublin, Lubuskie 20-093, Poland
  • Investigational Site Number : 6160071
    Lodz, Lódzkie 91-738, Poland
  • Investigational Site Number : 6160073
    Krakow, Malopolskie 31-503, Poland
  • Investigational Site Number : 6160072
    Sosnowiec, Slaskie 41-218, Poland
  • Investigational Site Number : 6430001
    Moscow, 115522, Russian Federation
  • Investigational Site Number : 6430062
    Moscow, 117198, Russian Federation
  • Investigational Site Number : 6430063
    Moscow, 119991, Russian Federation
  • Investigational Site Number : 7240050
    Esplugues de Llobregat, Catalunya [Cataluña] 08950, Spain
  • Investigational Site Number : 7240052
    Madrid, Madrid, Comunidad De 28046, Spain
  • Investigational Site Number : 7240053
    Madrid, 28009, Spain
  • Investigational Site Number : 7240051
    Valencia, 46026, Spain
  • Investigational Site Number : 8260031
    London, London, City Of WC1N 3JH, United Kingdom
  • Investigational Site Number : 8260033
    Liverpool, L12 2AP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Apr 2022, 67 months.

Results were first posted in Oct 2024, 2 years 6 months after primary completion. A results delay was requested in Apr 2023.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2016
First posted
May 18, 2016
StartActual
Sep 6, 2016
Primary completionActual
Apr 8, 2022
CompletionActual
Dec 27, 2023
Results delay requested
Apr 7, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02776735
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 18, 2016
Start date
Sep 6, 2016
Primary completion
Apr 8, 2022
Completion
Dec 27, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion